Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics

Feng, Xiaojun; Soldevila Verdeguer, Carla; Jafari, Samineh; Memariani, Zahra; Tewari, Devesh; Annunziata, Giuseppe; Barrea, Luigi; Hassan, Sherif T. S.; Smejkal, Karel; Malanik, Milan; Sychrova, Alice; Barreca, Davide; Ziberna, Lovro; Mahomoodally, Mohamad Fawzi; Zengin, Gokhan; Xu, Suowen; Nabavi, Seyed Mohammad; Shen, Ai-Zong

doi:10.7150/thno.30787

Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/17155

View

000461767700008.pdf (2.008Mb)

Identifiers

URI: http://hdl.handle.net/20.500.13003/17155

DOI: 10.7150/thno.30787

ISSN: 1838-7640

WOS ID: 000461767700008

Scopus EID: 2-s2.0-85065480668

PMID: 31037148

Embase PUI: L627547235

Metrics

Export

External links

Publication date

2019

Document type

review article

Citation

Feng X, Sureda A, Jafari S, Memariani Z, Tewari D, Annunziata G, et al. Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics. Theranostics. 2019;9(7):1923-51.

Abstract

Cardiovascular and metabolic diseases (CVMD) are the leading causes of death worldwide, underscoring the urgent necessity to develop new pharmacotherapies. Berberine (BBR) is an eminent component of traditional Chinese and Ayurvedic medicine for more than 2000 years. Recently, BBR has attracted much interest for its pharmacological actions in treating and/or managing CVMD. Recent discoveries of basic, translational and clinical studies have identified many novel molecular targets of BBR (such as AMPK, SIRT1, LDLR, PCSK9, and PTP1B) and provided novel evidences supporting the promising therapeutic potential of BBR to combat CVMD. Thus, this review provides a timely overview of the pharmacological properties and therapeutic application of BBR in CVMD, and underlines recent pharmacological advances which validate BBR as a promising lead drug against CVMD.